Morgan Stanley Maintains Equal-Weight on Seagen, Raises Price Target to $181
Morgan Stanley maintains Seagen (NASDAQ:SGEN) with a Equal-Weight and raises the price target from $167 to $181.
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Seattle Genetics Q3 EPS $(1.61) May Not Compare To $(0.57) Estimate, Sales $424.06M Beat $384.65M Estimate
Seattle Genetics (NASDAQ:SGEN) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.57) by 182.46 percent. This is a 146 percent decrease over earnings of $3.50 per share from
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
Seattle Genetics’s Earnings Outlook
Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.
Analysts estimate that Seattle Genetics will likely report an Earnings Per Share (EPS) of $-0.57
10 Biggest Price Target Changes For Wednesday
Raymond James raised Alphabet Inc. (NASDAQ: GOOGL) price target from $3,200 to $3,400. Alphabet shares fell 0.7% to $2,767.04 in pre-market trading.
SVB Leerink Maintains Outperform on Seagen, Raises Price Target to $200
SVB Leerink analyst Andrew Berens maintains Seagen (NASDAQ:SGEN) with a Outperform and raises the price target from $190 to $200.
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings.
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.
A Bullish Sign Appears On Seagen’s Chart
If history is any guide, there may be good fortune ahead for shares of Seagen(NASDAQ:SGEN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.